High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma (pages 1868–1875)
Michael J. Morris, Oren Smaletz, David Solit, W. Kevin Kelly, Susan Slovin, Carlos Flombaum, Tracy Curley, Anthony Delacruz, Lawrence Schwartz, Martin Fleisher, Andrew Zhu, Meghan Diani, Mary Fallon and Howard I. Scher
Version of Record online: 31 MAR 2004 | DOI: 10.1002/cncr.20185
In the current Phase I study, the authors examined the use of dose-escalated calcitriol (1,25-dihydroxycholecalciferol) with zoledronate and dexamethasone for the treatment of patients with progressive prostate carcinoma. The regimen was well tolerated, even at calcitriol doses as high as 30 μg 3 times per week; however, it was cumbersome to administer and had minimal activity.